MyoKardia Reports First Quarter 2016 Financial Results and Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
MyoKardia, Inc's (MYOK) MYK-461 HCM Study Should Show Clinical Benefit - Wedbush
May 13, 2016 8:03 AM EDTWedbush analyst, David M. Nierengarten, believes biomarker-based efficacy readouts from a Ph 1 study of MyoKardia (NASDAQ: MYOK) MYK-461 in HCM patients are expected this quarter, which should provide further evidence of the drugs activity. No change to Outperform rating or $22 price target
Top-line... More



